Integrated DNA Technologies Bolsters Synthetic Biology Portfolio with Launch of Rapid Genes and Significant Upgrades to Gene Synthesis Offerings
2024年8月6日 - 9:50PM
ビジネスワイヤ(英語)
Expanded gene offerings include new vector
options, transparent pricing and expedited turnaround times
To enable pharmaceutical researchers to move quickly into their
high‑throughput screening experiments, global genomics solutions
provider Integrated DNA Technologies (IDT) today released rapid
genes, a new offering in its synthetic biology portfolio. Available
from 125 base pairs (bp) to 2000 bp, IDT’s rapid genes are
ready-to-use, next generation sequencing (NGS)-verified clonal
genes shipped in as little as five business days. Rapid genes are
priced at $0.15 USD per bp and delivered in a plate format for
automated workflows.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240806051282/en/
“Fast genes are in IDT’s DNA. With rapid genes, customers can
expect faster turnaround times, consistent pricing and a trusted
partner that can deliver a complete solution to advance their drug
discovery work sooner,” said Sandy Ottensmann, VP/General Manager,
Gene Writing & Editing Business Unit at IDT. “This is all
enabled by the recent investment IDT has made with its synthetic
biology manufacturing operations and expanded footprint, in support
of the important work the pharmaceutical research community is
making to drive significant innovation in the bioeconomy and
accelerate the pace of genomics.”
Rapid genes are circular double-stranded DNA in a plasmid and
are available to ship dry or in a resuspension buffer in 96-well or
384-well plates. In addition to rapid genes, IDT is also rolling
out enhancements to its existing gene synthesis offerings,
including additional standard bacterial and mammalian expression
vectors, expanded yield up to 100 µg with endotoxin free option,
and 100% sequence verified, error-free clones. IDT’s rapid genes
and recent custom vector onboarding tool launches are the latest
addition to IDT’s broad synthetic biology portfolio comprised of
genes and gene fragments.
As a large-scale provider of synthetic DNA, IDT can make gene
fragments between 125 bp to 3 kb, and custom genes between 25 bp to
5 kb. Genes greater than 5 kb are available through custom quoting.
To place an order, request a custom quote or for more information,
visit www.idtdna.com/RapidGenes.
About IDT
For more than 35 years, Integrated DNA Technologies, Inc.
(IDT) has empowered genomics laboratories with an
oligonucleotide manufacturing process unlike anyone else in the
industry, featuring the most advanced synthesis, modification,
purification, and quality control capabilities available. Since its
founding in 1987, IDT has progressed from a leading oligo
manufacturer to a genomics solutions provider supporting key
application areas such as next generation sequencing, CRISPR genome
editing, synthetic biology, digital PCR, and RNA interference. IDT
manufactures products used by scientists researching many forms of
cancer and most inherited and infectious diseases.
Seeking to fulfill its mission of accelerating the pace of
genomics, IDT acquired Archer™ NGS Research Assays in December
2022. When combined with its existing solutions, the expanded
portfolio helps realize the shared vision of enabling researchers
to rapidly move from the lab to life-changing advances.
IDT’s infrastructure supports customers around the globe with
its manufacturing headquarters situated in Coralville, Iowa, USA,
with additional manufacturing sites in San Diego, California, USA;
Boulder, Colorado, USA; Research Triangle Park, North Carolina,
USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore.
IDT is proud to be part of Danaher. Danaher’s science and
technology leadership puts IDT’s solutions at the forefront of the
industry, so they can reach more people. Being part of Danaher
means we can offer unparalleled breadth and depth of expertise and
solutions to our customers.
Together with Danaher’s other businesses across Biotechnology,
Diagnostics and Life Sciences, we unlock the transformative
potential of cutting-edge science and technology to improve
billions of lives every day.
For more information about IDT, visit www.idtdna.com and follow
the company on LinkedIn, X, Facebook, YouTube, and Instagram.
Disclaimer: RUO — For research use only. Not for use in
diagnostic procedures. Unless otherwise agreed to in writing,
IDT does not intend these products to be used in clinical
applications and does not warrant their fitness or suitability for
any clinical diagnostic use.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240806051282/en/
Kristina Sarenas Director of PR 800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA) idtpr@idtdna.com